Pulmonary embolism in hospitalised patients with COVID-19.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
11 2020
Historique:
received: 28 05 2020
revised: 25 06 2020
accepted: 08 07 2020
pubmed: 19 7 2020
medline: 18 11 2020
entrez: 19 7 2020
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is characterised by dyspnoea and abnormal coagulation parameters, including raised D-dimer. Data suggests a high incidence of pulmonary embolism (PE) in ventilated patients with COVID-19. To determine the incidence of PE in hospitalised patients with COVID-19 and the diagnostic yield of Computer Tomography Pulmonary Angiography (CTPA) for PE. We also examined the utility of D-dimer and conventional pre-test probability for diagnosis of PE in COVID-19. Retrospective review of single-centre data of all CTPA studies in patients with suspected or confirmed COVID-19 identified from Electronic Patient Records (EPR). There were 1477 patients admitted with COVID-19 and 214 CTPA scans performed, of which n = 180 (84%) were requested outside of critical care. The diagnostic yield for PE was 37%. The overall proportion of PE in patients with COVID-19 was 5.4%. The proportions with Wells score of ≥4 ('PE likely') was 33/134 (25%) without PE vs 20/80 (25%) with PE (P = 0.951). The median National Early Warning-2 (NEWS2) score (illness severity) was 5 (interquartile range [IQR] 3-9) in PE group vs 4 (IQR 2-7) in those without PE (P = 0.133). D-dimer was higher in PE (median 8000 ng/mL; IQR 4665-8000 ng/mL) than non-PE (2060 ng/mL, IQR 1210-4410 ng/mL, P < 0.001). In the 'low probability' group, D-dimer was higher (P < 0.001) in those with PE but had a limited role in excluding PE. Even outside of the critical care environment, PE in hospitalised patients with COVID-19 is common. Of note, approaching half of PE events were diagnosed on hospital admission. More data are needed to identify an optimal diagnostic pathway in patients with COVID-19. Randomised controlled trials of intensified thromboprophylaxis are urgently needed.

Sections du résumé

BACKGROUND
Coronavirus disease 2019 (COVID-19) is characterised by dyspnoea and abnormal coagulation parameters, including raised D-dimer. Data suggests a high incidence of pulmonary embolism (PE) in ventilated patients with COVID-19.
OBJECTIVES
To determine the incidence of PE in hospitalised patients with COVID-19 and the diagnostic yield of Computer Tomography Pulmonary Angiography (CTPA) for PE. We also examined the utility of D-dimer and conventional pre-test probability for diagnosis of PE in COVID-19.
PATIENTS/METHODS
Retrospective review of single-centre data of all CTPA studies in patients with suspected or confirmed COVID-19 identified from Electronic Patient Records (EPR).
RESULTS
There were 1477 patients admitted with COVID-19 and 214 CTPA scans performed, of which n = 180 (84%) were requested outside of critical care. The diagnostic yield for PE was 37%. The overall proportion of PE in patients with COVID-19 was 5.4%. The proportions with Wells score of ≥4 ('PE likely') was 33/134 (25%) without PE vs 20/80 (25%) with PE (P = 0.951). The median National Early Warning-2 (NEWS2) score (illness severity) was 5 (interquartile range [IQR] 3-9) in PE group vs 4 (IQR 2-7) in those without PE (P = 0.133). D-dimer was higher in PE (median 8000 ng/mL; IQR 4665-8000 ng/mL) than non-PE (2060 ng/mL, IQR 1210-4410 ng/mL, P < 0.001). In the 'low probability' group, D-dimer was higher (P < 0.001) in those with PE but had a limited role in excluding PE.
CONCLUSIONS
Even outside of the critical care environment, PE in hospitalised patients with COVID-19 is common. Of note, approaching half of PE events were diagnosed on hospital admission. More data are needed to identify an optimal diagnostic pathway in patients with COVID-19. Randomised controlled trials of intensified thromboprophylaxis are urgently needed.

Identifiants

pubmed: 32682004
pii: S0049-3848(20)30316-9
doi: 10.1016/j.thromres.2020.07.025
pmc: PMC7351054
pii:
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

95-99

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):492-6
pubmed: 9279229
BMJ. 2012 Oct 04;345:e6564
pubmed: 23036917
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
BMC Res Notes. 2019 Jan 18;12(1):41
pubmed: 30658690
Emerg Radiol. 2014 Apr;21(2):133-41
pubmed: 24185370
Clin Med (Lond). 2017 Jun;17(Suppl 3):s5
pubmed: 30958767
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
AJR Am J Roentgenol. 2008 Aug;191(2):471-4
pubmed: 18647919
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Ann Intern Med. 1998 Dec 15;129(12):997-1005
pubmed: 9867786
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134
pubmed: 32119647
Thromb Haemost. 2020 May;120(5):876-878
pubmed: 32246450
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619863495
pubmed: 31298057
Thromb Res. 2020 Sep;193:1-4
pubmed: 32485437
Thromb Res. 2020 Sep;193:86-89
pubmed: 32531548
J Thromb Haemost. 2017 Apr;15(4):678-684
pubmed: 28106338
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Thromb Res. 2007;120(2):281-8
pubmed: 17030057
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Chin Med J (Engl). 2014;127(11):2025-9
pubmed: 24890146
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094

Auteurs

Martin B Whyte (MB)

Dept of Medicine, King's College NHS Foundation Trust, London, UK; Dept Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.

Philip A Kelly (PA)

Dept of Medicine, King's College NHS Foundation Trust, London, UK.

Elisa Gonzalez (E)

Dept of Medicine, King's College NHS Foundation Trust, London, UK.

Roopen Arya (R)

King's Thrombosis Centre, Department of Haematological Medicine, King's College NHS Foundation Trust, London, UK.

Lara N Roberts (LN)

King's Thrombosis Centre, Department of Haematological Medicine, King's College NHS Foundation Trust, London, UK. Electronic address: lara.roberts@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH